BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 2014;31:754-67. [PMID: 24065592 DOI: 10.1007/s11095-013-1197-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Smits A, De Cock RF, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CA. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. Antimicrob Agents Chemother 2015;59:6344-51. [PMID: 26248375 DOI: 10.1128/AAC.01157-15] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 5.2] [Reference Citation Analysis]
2 De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res 2014;31:2643-54. [PMID: 24789450 DOI: 10.1007/s11095-014-1361-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
3 Brussee JM, Calvier EA, Krekels EH, Välitalo PA, Tibboel D, Allegaert K, Knibbe CA. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev Clin Pharmacol 2016;9:1235-44. [PMID: 27269200 DOI: 10.1080/17512433.2016.1198256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
4 Abduljalil K, Jamei M, Rostami-Hodjegan A, Johnson TN. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. AAPS J 2014;16:568-76. [PMID: 24700271 DOI: 10.1208/s12248-014-9592-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
5 Zhou W, Johnson TN, Xu H, Cheung S, Bui KH, Li J, Al-Huniti N, Zhou D. Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children. CPT Pharmacometrics Syst Pharmacol 2016;5:475-83. [PMID: 27566992 DOI: 10.1002/psp4.12101] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
6 Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci 2017;109S:S22-6. [PMID: 28502674 DOI: 10.1016/j.ejps.2017.05.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
7 Rivera-Chaparro ND, Cohen-Wolkowiez M, Greenberg RG. Dosing antibiotics in neonates: review of the pharmacokinetic data. Future Microbiol 2017;12:1001-16. [PMID: 28758800 DOI: 10.2217/fmb-2017-0058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Allegaert K, Simons SHP, Tibboel D, Krekels EH, Knibbe CA, van den Anker JN. Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology. Eur J Pharm Sci 2017;109S:S27-31. [PMID: 28506866 DOI: 10.1016/j.ejps.2017.05.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
9 Bijleveld YA, de Haan TR, van der Lee HJ, Groenendaal F, Dijk PH, van Heijst A, de Jonge RC, Dijkman KP, van Straaten HL, Rijken M, Zonnenberg IA, Cools F, Zecic A, Nuytemans DH, van Kaam AH, Mathot RA; PharmaCool study group. Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia. Br J Clin Pharmacol 2016;81:1067-77. [PMID: 26763684 DOI: 10.1111/bcp.12883] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
10 Allegaert K, van den Anker JN. Clinical pharmacology in neonates: small size, huge variability. Neonatology 2014;105:344-9. [PMID: 24931327 DOI: 10.1159/000360648] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
11 van den Anker J, Allegaert K. Rational Use of Antibiotics in Neonates: Still in Search of Tailored Tools. Healthcare (Basel) 2019;7:E28. [PMID: 30781454 DOI: 10.3390/healthcare7010028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Krekels EHJ, Knibbe CAJ. Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories. Handb Exp Pharmacol 2020;261:231-55. [PMID: 31598838 DOI: 10.1007/164_2019_250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Eidelman C, Abdel-rahman SM. Pharmacokinetic considerations when prescribing in children. International Journal of Pharmacokinetics 2016;1:69-80. [DOI: 10.4155/ipk-2016-0001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
14 Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates. Arch Dis Child 2016;101:377-81. [DOI: 10.1136/archdischild-2013-305309] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
15 Balevic SJ, Cohen-Wolkowiez M. Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children. J Clin Pharmacol 2018;58 Suppl 10:S58-72. [PMID: 30248192 DOI: 10.1002/jcph.1053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
16 Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol 2014;10:1069-78. [PMID: 24961300 DOI: 10.1517/17425255.2014.931937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
17 van den Anker J, Allegaert K. Considerations for Drug Dosing in Premature Infants. J Clin Pharmacol 2021;61 Suppl 1:S141-51. [PMID: 34185893 DOI: 10.1002/jcph.1884] [Reference Citation Analysis]
18 Allegaert K. Better medicines for neonates: Improving medicine development, testing, and prescribing. Early Hum Dev 2017;114:22-5. [PMID: 28899617 DOI: 10.1016/j.earlhumdev.2017.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. Clin Pharmacokinet 2015;54:1183-204. [PMID: 26138291 DOI: 10.1007/s40262-015-0298-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 11.6] [Reference Citation Analysis]
20 Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert Opin Drug Metab Toxicol 2016;12:367-75. [PMID: 26817821 DOI: 10.1517/17425255.2016.1147559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
21 Krekels EH, Tibboel D, Knibbe CA. Pediatric pharmacology: current efforts and future goals to improve clinical practice. Expert Opin Drug Metab Toxicol 2015;11:1679-82. [PMID: 26166262 DOI: 10.1517/17425255.2015.1065815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
22 Allegaert K, Smits A, van den Anker JN. Drug evaluation studies in neonates: how to overcome the current limitations. Expert Rev Clin Pharmacol 2018;11:387-96. [PMID: 29421929 DOI: 10.1080/17512433.2018.1439378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister M. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. J Clin Pharmacol 2016;56:909-35. [PMID: 26766774 DOI: 10.1002/jcph.705] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
24 Cristea S, Smits A, Kulo A, Knibbe CAJ, van Weissenbruch M, Krekels EHJ, Allegaert K. Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia. Antimicrob Agents Chemother 2017;61:e01282-17. [PMID: 28993332 DOI: 10.1128/AAC.01282-17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
25 Valitalo PA, van den Anker JN, Allegaert K, de Cock RF, de Hoog M, Simons SH, Mouton JW, Knibbe CA. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. J Antimicrob Chemother 2015;70:2074-7. [PMID: 25766737 DOI: 10.1093/jac/dkv052] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
26 Sasano H, Aoki K, Arakawa R, Hanada K. Population Pharmacokinetic Analysis and Dose Regimen Optimization in Japanese Infants with an Extremely Low Birth Weight. Antimicrob Agents Chemother 2021;65:e02523-20. [PMID: 33318009 DOI: 10.1128/AAC.02523-20] [Reference Citation Analysis]
27 Samardzic J, Turner MA, Bax R, Allegaert K. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol 2015;11:1041-52. [PMID: 25958820 DOI: 10.1517/17425255.2015.1046433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
28 Petit C, Jullien V, Samson A, Guedj J, Kiechel JR, Zohar S, Comets E. Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. Antimicrob Agents Chemother 2015;60:1481-91. [PMID: 26711749 DOI: 10.1128/AAC.01125-15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Nguyen D, Shaik JS, Tai G, Tiffany C, Perry C, Dumont E, Gardiner D, Barth A, Singh R, Hossain M. Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague. Br J Clin Pharmacol 2021. [PMID: 34289143 DOI: 10.1111/bcp.14996] [Reference Citation Analysis]
30 Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Ther Drug Monit 2015;37:756-65. [PMID: 26562817 DOI: 10.1097/FTD.0000000000000216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
31 Bijleveld YA, de Haan TR, van der Lee JH, Groenendaal F, Dijk PH, van Heijst A, de Jonge RCJ, Dijkman KP, van Straaten HLM, Rijken M, Zonnenberg IA, Cools F, Zecic A, Nuytemans DHGM, van Kaam AH, Mathôt RAA; PharmaCool Study Group. Evaluation of a System-Specific Function To Describe the Pharmacokinetics of Benzylpenicillin in Term Neonates Undergoing Moderate Hypothermia. Antimicrob Agents Chemother 2018;62:e02311-17. [PMID: 29378710 DOI: 10.1128/AAC.02311-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Zhao W, Leroux S, Jacqz-Aigrain E. Dosage individualization in children: integration of pharmacometrics in clinical practice. World J Pediatr 2014;10:197-203. [PMID: 25124969 DOI: 10.1007/s12519-014-0493-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
33 Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ. Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Pharm Res 2019;36:112. [PMID: 31147853 DOI: 10.1007/s11095-019-2651-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Smits A, De Cock P, Vermeulen A, Allegaert K. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin Drug Metab Toxicol 2019;15:25-34. [PMID: 30554542 DOI: 10.1080/17425255.2019.1558205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
35 Van Donge T, Mian P, Tibboel D, Van Den Anker J, Allegaert K. Drug metabolism in early infancy: opioids as an illustration. Expert Opin Drug Metab Toxicol 2018;14:287-301. [PMID: 29363349 DOI: 10.1080/17425255.2018.1432595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
36 Janssen EJ, Välitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother 2016;60:1013-21. [PMID: 26643337 DOI: 10.1128/AAC.01968-15] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 7.2] [Reference Citation Analysis]
37 Ward RM, Allegaert K, de Groot R, van den Anker JN. Commentary: Continuous infusion of vancomycin in neonates: to use or not to use remains the question. Pediatr Infect Dis J 2014;33:606-7. [PMID: 24378934 DOI: 10.1097/INF.0000000000000244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Calvier EAM, Krekels EHJ, Yu H, Välitalo PAJ, Johnson TN, Rostami-Hodjegan A, Tibboel D, van der Graaf PH, Danhof M, Knibbe CAJ. Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. CPT Pharmacometrics Syst Pharmacol 2018;7:175-85. [PMID: 29399979 DOI: 10.1002/psp4.12273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
39 An G. The Utility of Pharmacometric Models in Clinical Pharmacology Research in Infants. Curr Pharmacol Rep 2020;6:260-6. [PMID: 33767946 DOI: 10.1007/s40495-020-00234-5] [Reference Citation Analysis]
40 Coppini R, Simons SHP, Mugelli A, Allegaert K. Clinical research in neonates and infants: Challenges and perspectives. Pharmacol Res 2016;108:80-7. [PMID: 27142783 DOI: 10.1016/j.phrs.2016.04.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
41 Van den Anker JN, McCune S, Annaert P, Baer GR, Mulugeta Y, Abdelrahman R, Wu K, Krudys KM, Fisher J, Slikker W, Chen C, Burckart GJ, Allegaert K. Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs. Pharmaceutics 2020;12:E685. [PMID: 32698409 DOI: 10.3390/pharmaceutics12070685] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
42 Liu X, Smits A, Wang Y, Renard M, Wead S, Kagan RJ, Healy DP, De Cock P, Allegaert K, Sherwin CM. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. Therapeutic Drug Monitoring 2019;41:44-52. [DOI: 10.1097/ftd.0000000000000568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
43 Girardi A, Raschi E, Galletti S, Poluzzi E, Faldella G, Allegaert K, De Ponti F. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf 2015;38:535-51. [PMID: 25863473 DOI: 10.1007/s40264-015-0288-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
44 Allegaert K, Smits A, van Donge T, van den Anker J, Sarafidis K, Levtchenko E, Mekahli D. Renal Precision Medicine in Neonates and Acute Kidney Injury: How to Convert a Cloud of Creatinine Observations to Support Clinical Decisions. Front Pediatr 2020;8:366. [PMID: 32850523 DOI: 10.3389/fped.2020.00366] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
45 van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental Changes in Pharmacokinetics and Pharmacodynamics. The Journal of Clinical Pharmacology 2018;58:S10-25. [DOI: 10.1002/jcph.1284] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 21.3] [Reference Citation Analysis]
46 Girardi A, Raschi E, Galletti S, Allegaert K, Poluzzi E, De Ponti F. Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development. Expert Opin Drug Metab Toxicol 2017;13:555-65. [PMID: 28141945 DOI: 10.1080/17425255.2017.1290081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Smits A, Kulo A, van den Anker J, Allegaert K. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Expert Opin Drug Metab Toxicol 2017;13:157-66. [PMID: 27623706 DOI: 10.1080/17425255.2017.1234606] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
48 Brussee JM, Krekels EHJ, Calvier EAM, Palić S, Rostami-Hodjegan A, Danhof M, Barrett JS, de Wildt SN, Knibbe CAJ. A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. AAPS J 2019;21:81. [PMID: 31250333 DOI: 10.1208/s12248-019-0351-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Barrett JS, Barrett RF, Vinks AA. Status Toward the Implementation of Precision Dosing in Children. J Clin Pharmacol 2021;61 Suppl 1:S36-51. [PMID: 34185896 DOI: 10.1002/jcph.1830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Cristea S, Allegaert K, Falcao AC, Falcao F, Silva R, Smits A, Knibbe CAJ, Krekels EHJ. Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. Antimicrob Agents Chemother 2019;63:e00853-19. [PMID: 31182538 DOI: 10.1128/AAC.00853-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
51 Bhongsatiern J, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB, Sherwin CM. Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance? J Clin Pharmacol 2016;56:528-40. [PMID: 26412385 DOI: 10.1002/jcph.650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]